Boston Scientific (BSX) Total Non-Current Liabilities (2009 - 2026)

Boston Scientific (BSX) has 18 years of Total Non-Current Liabilities data on file, last reported at $41.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 9.66% year-over-year to $41.9 billion; the trailing twelve-month figure through Mar 2026 stood at $41.9 billion (up 9.66% YoY), and the FY2025 full-year result was $41.3 billion, up 9.97% from the prior year.
• Total Non-Current Liabilities advanced to $41.9 billion in Q1 2026, from $41.3 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $41.9 billion in Q1 2026 to a low of $30.0 billion in Q3 2022.
• A 5-year average of $34.9 billion and a median of $34.8 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities gained 1.42% in 2022 and climbed 13.13% in 2024, its largest moves.
• Tracing BSX's Total Non-Current Liabilities over 5 years: stood at $30.4 billion in 2022, then climbed by 8.99% to $33.2 billion in 2023, then advanced by 13.13% to $37.5 billion in 2024, then gained by 9.97% to $41.3 billion in 2025, then rose by 1.49% to $41.9 billion in 2026.
• Business Quant data shows BSX's Total Non-Current Liabilities at $41.9 billion in Q1 2026, $41.3 billion in Q4 2025, and $40.3 billion in Q3 2025.